SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC reports loss in Q1 at Rs 10.08 crore

08 Aug 2011 Evaluate

Sun Pharma Advanced Research Company (SPARC) reported unaudited results for the first quarter ended June 30, 2011.

The company posted a net loss of Rs 11.26 crore for the first quarter ended June 30, 2011 against net profit of Rs 48 lakh in the same period previous fiscal. The company's total income declined by 31.57% at Rs 10.08 crore in the June quarter, while the same was Rs 14.73 crore in the corresponding period of last financial year.

SPARC is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).

Sun Pharma Adv. Res Share Price

172.85 5.90 (3.53%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 458.00
Indegene 529.65
CMS Info Systems 290.00
JITF Infralogistics 307.90
Sagility 44.18
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×